Compare Organon & Co. Common Stock (OGN) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Wolfspeed Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wolfspeed Inc trades at $24.05 (market cap $1.51B). The key difference: Organon & Co. Common Stock is far larger — about 2.4× Wolfspeed Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wolfspeed Inc for 20 Days on average.
| OGN | WOLF | |
|---|---|---|
Market Cap | $3.62B | $1.51B |
Volume | 2,892,999 | 3,682,639 |
Sector | Health | Technology |
52-Week High | $13.81 | $73.68 |
52-Week Low | $5.70 | $14.80 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $11.04B | $2.22B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wolfspeed (WOLF) trades at $28.67, up 2.25% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The company shows severe financial strain with negative gross margins of -16.05% and net losses of -$1.61B in 2025, though 2026 projects a return to profitability. Recent news highlights expansion of 200mm silicon carbide technology and ongoing investor litigation investigations.
The stock presents high-risk speculative potential with analyst consensus target of $54.32 suggesting significant upside, but requires successful execution on revenue growth and margin improvement. Key risks include persistent negative profitability, high debt burden, and competitive pressures in the semiconductor materials sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
